Compound Summary
Pirenperone
Compound Information
Pirenperone
Compound Name: | Pirenperone |
Compound CID: | 4847 |
Synonyms: | Pirenperone 75444-65-4 R-47,465 UNII-Y9FMC4513X 3-2-4-(4-fluorobenzoyl)piperidin-1-ylethyl-2-methylpyrido1,2-apyrimidin-4-one More... |
Iupac Name: | 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-one |
InChI: | InChI=1S/C23H24FN3O2/c1-16-20(23(29)27-12-3-2-4-21(27)25-16)11-15-26-13-9-18(10-14-26)22(28)17-5-7-19(24)8-6-17/h2-8,12,18H,9-11,13-15H2,1H3 |
InChIKey: | HXCNRYXBZNHDNE-UHFFFAOYSA-N |
Canonical Smiles: | CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F |
Isomeric Smiles: | CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F |
Molecular Weight: | 393.5 |
Molecular Formula: | C23H24FN3O2 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Pirenperone
Molecular Weight: | 393.5 |
Molecular Formula: | C23H24FN3O2 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptor Count: | 5 |
Rotatable Bond Count: | 5 |
Heavy Atom Count: | 29 |
Complexity: | 782 |
Synonyms
Pirenperone
| Pirenperone | Pirenperone |
|---|---|
Pirenperone |
75444-65-4 |
R-47,465 |
UNII-Y9FMC4513X |
3-2-4-(4-fluorobenzoyl)piperidin-1-ylethyl-2-methylpyrido1,2-apyrimidin-4-one |
CHEMBL18331 |
3-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl)-2-methyl-4H-pyrido1,2-apyrimidin-4-one |
MLS000069365 |
Y9FMC4513X |
NCGC00015784-07 |
SMR000058507 |
DSSTox_CID_25182 |
DSSTox_RID_80730 |
DSSTox_GSID_45182 |
R 47465 |
Pirenperona |
Pirenperonum |
Pirenperonum INN-Latin |
Pirenperona INN-Spanish |
CAS-75444-65-4 |
SR-01000002998 |
EINECS 278-213-5 |
Pirenperone USAN:INN:BAN |
Prestwick_858 |
Spectrum_001584 |
SpecPlus_000663 |
Lopac-P-126 |
Opera_ID_1876 |
Prestwick0_000531 |
Prestwick1_000531 |
Prestwick2_000531 |
Prestwick3_000531 |
Spectrum2_001680 |
Spectrum3_001655 |
Spectrum4_000620 |
Spectrum5_001827 |
Pirenperone (USAN/INN) |
3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one |
4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2-methyl- |
Pirenperone, >97%, solid |
Lopac0_001007 |
R-47465 |
BSPBio_000541 |
BSPBio_003409 |
GTPL283 |
KBioGR_001180 |
KBioSS_002064 |
MLS001148188 |
MLS001424212 |
DivK1c_006759 |
SCHEMBL467209 |
SPECTRUM1504188 |
SPBio_001899 |
SPBio_002462 |
BPBio1_000597 |
DTXSID9045182 |
CHEBI:92444 |
KBio1_001703 |
KBio2_002064 |
KBio2_004632 |
KBio2_007200 |
KBio3_002629 |
HMS1569L03 |
HMS1922F15 |
HMS2051H22 |
HMS2093C08 |
HMS2096L03 |
HMS2234F07 |
HMS3263I15 |
HMS3370M02 |
HMS3393H22 |
HMS3713L03 |
Pharmakon1600-01504188 |
ZINC538194 |
Tox21_110220 |
Tox21_501007 |
BDBM50024205 |
CCG-39087 |
MFCD00069332 |
NSC760095 |
Tox21_110220_1 |
LP01007 |
NC00316 |
NSC 760095 |
NSC-760095 |
SDCCGSBI-0050980.P004 |
3-2-4-(4-Fluorobenzoyl)-1-piperidinylethyl-2-methyl-4H-pyrido-1,2-a pyrimidin-4-one |
3-2-4-(4-fluorobenzoyl)piperidin-1-ylethyl-2-methylpyrido2,1-bpyrimidin-4-one |
4H-Pyrido1,2-apyrimidin-4-one,3-2-4-(4-fluorobenzoyl)-1-piperidinylethyl-2-methyl- |
NCGC00015784-01 |
NCGC00015784-02 |
NCGC00015784-03 |
NCGC00015784-04 |
NCGC00015784-05 |
NCGC00015784-06 |
NCGC00015784-08 |
NCGC00015784-09 |
NCGC00015784-10 |
NCGC00015784-11 |
NCGC00015784-12 |
NCGC00015784-14 |
NCGC00015784-19 |
NCGC00021326-03 |
NCGC00021326-04 |
NCGC00021326-05 |
NCGC00021326-06 |
NCGC00178084-01 |
NCGC00178084-02 |
NCGC00261692-01 |
SBI-0050980.P003 |
CAS- 75444-65-4 |
EU-0101007 |
FT-0732988 |
P-126 |
S0779 |
VU0239628-6 |
D05495 |
AB00053292_16 |
L000956 |
SR-01000002998-2 |
SR-01000002998-5 |
SR-01000002998-7 |
BRD-K25224017-001-05-2 |
BRD-K25224017-001-15-1 |
Q27088400 |
3-2-4-(4-fluorobenzoyl)-1-piperidinylethyl-2-methyl-4H-pyrido1,2-apyrimidin-4-one |
3-{2-4-(4-Fluoro-benzoyl)-piperidin-1-yl-ethyl}-2-methyl-pyrido1,2-apyrimidin-4-one |
3-{2-4-(4-Fluoro-benzoyl)-piperidin-1-yl-ethyl}-2-methyl-pyrido1,2-apyrimidin-4-one(Pirenperone) |
3-{2-4-(4-Fluorobenzoyl)-1-piperidinylethyl}-2-methyl- 4H-pyrido1,2-apyrimidine-4-one |
Experimental Data
Pirenperone
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 10.000000000000000 | umol/L | 16.580000000000000 | 16.020000000000000 | -3.383000000000000 | NS | N2 | 33008901 | Inactive | ||||
| Caenorhabditis elegans | 100.000000000000000 | umol/L | 15.160000000000000 | 15.500000000000000 | 2.240000000000000 | NS | N2 | 33008901 | Inactive | ||||
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 8.000000000000000 | NS | N2 | 24134630 | Inactive | ||||||
| Drosophila melanogaster | 200.000000000000000 | umol/L | 46.640000000000000 | 48.260000000000000 | 3.480000000000000 | NS | MALES | 33008901 | Inactive | ||||
| Drosophila melanogaster | 20.000000000000000 | umol/L | 46.240000000000000 | 49.540000000000000 | 7.148000000000000 | S | FEMALES | 33008901 | Active |
Experimental Data Visualization
Pirenperone
Statistics Data
Pirenperone
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 8.000000000000000 | 2 | 3 | |
| Drosophila melanogaster | 7.148000000000000 | 1 | 2 |
Statistics Data Visualization
Pirenperone
